THE USE OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH HEMOPHILIA
Author:
Open Access
- 1 January 2020
- journal article
- research article
- Published by Grodno State Medical University in Hepatology and Gastroenterology
- Vol. 4 (2) , 184-188
Abstract
Background. Worldwide, prior to 1990, a large number of patients with hemophilia were infected with the hepatitis C virus due to substitution therapy. The mortality rate from chronic liver disease and HCC in patients with HCV and hemophilia is signifcantly higher than in general population. Objective. To assess the results of direct-acting antiviral therapy in patients with hemophilia and chronic hepatitis C. Material and methods. The rate of sustained virologic response after DAA treatment and the dynamics of clinical and laboratory parameters during antiviral treatment were evaluated. Results. All 14 patients achieved sustained virological response after 12 / 24 weeks of treatment. During antiviral treatment, some patients showed an increase in blood urea nitrogen, a decrease in leukocyte count, and increase of ALT activity. All these phenomena were reversible and resolved spontaneously. Conclusion. The DAA regimens available in Belarus are highly effective for the treatment of chronic hepatitis C in patients with hemophilia. These regimens do not signifcantly affect hematological parameters, are well tolerated, and have acceptable safety profle.Keywords
This publication has 6 references indexed in Scilit:
- EASL Recommendations on Treatment of Hepatitis C 2018Journal of Hepatology, 2018
- Management of HCV-Related Liver Disease in Hemophilia and ThalassemiaSeminars in Liver Disease, 2018
- Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and managementAnnals of Gastroenterology, 2018
- Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohortAmerican Journal of Hematology, 2016
- Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysisJournal of Antimicrobial Chemotherapy, 2008
- Management of hepatitis C in the hemophilia patientThe American Journal of Medicine, 1999